Targeted therapies for triple-negative breast cancer: combating a stubborn disease
Triple-negative breast cancers (TNBCs) constitute a heterogeneous subtype of breast
cancers that have a poor clinical outcome. Although no approved targeted therapy is …
cancers that have a poor clinical outcome. Although no approved targeted therapy is …
A recent update on small‐molecule kinase inhibitors for targeted cancer therapy and their therapeutic insights from mass spectrometry‐based proteomic analysis
Kinases are key regulatory signalling proteins governing numerous essential biological
processes and cellular functions. Dysregulation of many protein kinases is associated with …
processes and cellular functions. Dysregulation of many protein kinases is associated with …
Turning liabilities into opportunities: Off-target based drug repurposing in cancer
Targeted drugs and precision medicine have transformed the landscape of cancer therapy
and significantly improved patient outcomes in many cases. However, as therapies are …
and significantly improved patient outcomes in many cases. However, as therapies are …
Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer
G Cheng, X Fan, M Hao, J Wang, X Zhou, X Sun - Molecular cancer, 2016 - Springer
Background Tissue inhibitor of metalloproteinases-1 (TIMP-1) is a multifunctional protein
that can directly regulate apoptosis and metastasis. In this study, we investigated the …
that can directly regulate apoptosis and metastasis. In this study, we investigated the …
Predicting and overcoming chemotherapeutic resistance in breast cancer
KH Chun, JH Park, S Fan - Translational Research in Breast Cancer …, 2017 - Springer
Our understanding of breast cancer and its therapeutic approach has improved greatly due
to the advancement of molecular biology in recent years. Clinically, breast cancers are …
to the advancement of molecular biology in recent years. Clinically, breast cancers are …
Targeting epithelial–mesenchymal plasticity in cancer: clinical and preclinical advances in therapy and monitoring
The concept of epithelial–mesenchymal plasticity (EMP), which describes the dynamic flux
within the spectrum of phenotypic states that invasive carcinoma cells may reside, is being …
within the spectrum of phenotypic states that invasive carcinoma cells may reside, is being …
Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells
Background Triple negative breast cancer (TNBC) is a highly heterogeneous and
aggressive type of cancer that lacks effective targeted therapy. Despite detailed molecular …
aggressive type of cancer that lacks effective targeted therapy. Despite detailed molecular …
Materials, workflows and applications of IMAC for phosphoproteome profiling in the recent decade: A review
R Tang, Q Bai, S Ma, J Ou - TrAC Trends in Analytical Chemistry, 2023 - Elsevier
The last ten years have witnessed the increasingly notable advances in immobilized metal
ion chromatography (IMAC) for phosphoproteomic profiling. Protein phosphorylation is an …
ion chromatography (IMAC) for phosphoproteomic profiling. Protein phosphorylation is an …
ANP 32E induces tumorigenesis of triple‐negative breast cancer cells by upregulating E2F1
Triple‐negative breast cancer (TNBC) lacks expression of estrogen receptor (ER),
progesterone receptor, and the HER 2 receptor; it is highly proliferative and becomes the …
progesterone receptor, and the HER 2 receptor; it is highly proliferative and becomes the …
[HTML][HTML] Emerging therapies for acute myeloid leukemia: translating biology into the clinic
S Kavanagh, T Murphy, A Law, D Yehudai, JM Ho… - JCI insight, 2017 - ncbi.nlm.nih.gov
Acute myeloid leukemia (AML) is an aggressive hematological malignancy with a poor
outcome; overall survival is approximately 35% at two years and some subgroups have a …
outcome; overall survival is approximately 35% at two years and some subgroups have a …